Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CTAG2 encodes an autoimmunogenic tumor antigen that belongs to the ESO/LAGE family of cancer-testis antigens. Additionally we are shipping Cancer/testis Antigen 2 Proteins (5) and and many more products for this protein.
Showing 10 out of 40 products:
The tumor suppressor function of LSAMP is most likely exerted by reducing the proliferation rate of the tumor cells, possibly by indirectly upregulating one or more of the genes HES1, CTAG2 or KLF10.
NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine
LAGE-1a and NY-ESO-1 homology cannot be easily exploited in an anti-NY-ESO-1 vaccine given the low frequency of protein expression detected by IHC or serum analysis.
Spontaneous LAGE-1-specific CD4-positive T cells isolated from patients with advanced LAGE-1-positive/NY-ESO-1-positive melanoma are directed against three promiscuous and immunodominant epitopes.
CD4+ T cell clones specific for alternatively translated tumor antigen CAMEL have been isolated from the peripheral blood of a melanoma patient; CAMEL(81-102) is described as a naturally processed epitope recognized and presented by HLA-DR11 and HLA-DR12.
Data showed aberrant expression of NY-ESO-1 and LAGE-1 by IHC/RT-PCR in a significant proportion of epithelial ovarian cancer patients.
Data support the immunogenicity of NY-ESO-1/LAGE-1 ORF2 gene products and clearly demonstrate their capability to stimulate T-helper 1 type CD4+ T cells.
LAGE-1 expression was more frequently found in squamous cell carcinoma than in adenocarcinoma.
Isolation of CD4+ T cell clones from T cell cultures of two healthy donors leads to identification of four naturally processed HLA-DR-binding CAMEL epitopes, interesting peptides to investigate for future cancer immunotherapy.
first peptide epitope recognized by sera from a wide spectrum of cancer patients but not healthy donors
LAGE-1 expression was detected in esophageal cancer by cDNA RDA. LAGE-1 might have the potential to be a target antigen for anti-tumoral immunotherapy in esophageal cancers because of its tumor-specific expression similar to that of MAGE-A1.
There is a high frequency of the LAGE-1 gene allele with SNPs in coding regions in cancer patients.
MAGEC1/CT7, MAGEA3/6 and LAGE-1 are good candidates for immunotherapy, since together they cover 85% of the multiple myeloma cases.
We evaluated the correlations among the expression levels of NY-ESO-1, LAGE-1 and SSX-1 and clinical parameters in hepatocellular carcinoma patients
This gene encodes an autoimmunogenic tumor antigen that belongs to the ESO\\/LAGE family of cancer-testis antigens. This protein is expressed in a wide array of cancers including melanoma, breast cancer, bladder cancer and prostate cancer. This protein is also expressed in normal testis tissue. An alternative open reading frame product of this gene has been described in PMID 10399963. This alternate protein, termed CAMEL, is a tumor antigen that is recognized by melanoma-specific cytotoxic T-lymphocytes. Alternate splicing results in multiple transcript variants.
CTL-recognized antigen on melanoma
, LAGE-1a protein
, autoimmunogenic cancer/testis antigen NY-ESO-2
, cancer/testis antigen 6.2
, cancer/testis antigen family 6, member 2a
, cancer/testis antigen family 6, member 2b
, l antigen family member 1